This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
A PROPERTY UNIT of GT Capital Holdings, Inc. has sealed a deal with Metro Pacific Investments Corp.’s (MPIC) logistics arm to sell its Cavite property for P1.02 billion.
GTCXY PSKXF GTCAP PX MPCFF MPCIY MPI PXMFF PHSXY PSE PXMFY
TEN Philippine companies made it to the Nikkei Asian Review’s third annual list of Asia300 Power Performers Ranking, which ranks the most powerful and valuable listed companies in Asia.
JGSMY GTCAP GTCXY JGS CEBUY JBFCF MPCFF SPHXF SPHZF CEB JGSHF UVRBF AYAAF DMC MPCIY AYAAY JBFCY DMCIF UVRBY DMCP SMPH CEBUF MPI SPHXY JFC URC DMCHY ALI
Ty family-led conglomerate GT Capital Holdings is set to invest up to $200 million in shares of Japanese powerhouse Toyota Motor Corp., citing attractive valuation of the world’s largest automotive manufacturer.
GTCXY PSKXF GTCAP TM 7203 TYT PHSXY PSE TOYOF
GT Capital Holdings, Inc. is making its first offshore investment, as it buys up to ¥22.2 billion (around $200 million or P10.7 billion) worth of shares in Japanese auto giant Toyota Motor Corp.
GTCXY GTCAP TM 7203 TYT TOYOF
GT Capital Holdings, Inc. is investing 22.2 billion Japanese yen, or around $200 million, in Japanese auto manufacturer Toyota Motor Corp., noting that it is “timely” to invest in the world’s fifth largest firm.
GTCXY GTCAP TM 7203 TYT TOYOF
THE logistics unit of Metro Pacific Investments Corp. (MPIC) will be setting aside P8 billion for the development of warehouses in Cavite, as it aims to become a leading player in the logistics space.
FPAFY GTCXY GTCAP PSKXF MPCIY PXMFF 0142 PX FPAFF MPI MPCFF PHSXY PSE PXMFY
The benchmark Philippine Stock Exchange index (PSEi) closed lower yesterday as investors pocketed profits amid recent gains.
ICT JGSMY GTCAP GTCXY NOW JGS BDOUY ICTEF BDOUF PHSXY PSE SPHXF SPHZF JGSHF UVRBF AYAAF PSKXF AYAAY UVRBY SMPH BDO SPHXY URC DNOW ALI
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DMC DSLV GTCXY GTCAP VIIX DGLD CSSLF VIIZ DMCIF CS DMCP CSGKF UGLD ZIV USLV TVIX DMCHY XIV
The benchmark Philippine Stock Exchange index (PSEi) managed to close with a small gain on Wednesday, a day after inflation fears eased with the release of data for May.
GTCAP GTCXY GTMEY BDOUY BDOUF JBFCF PHSXY GTMEF PSE SPHXF SPHZF GLOPA AYAAF PSKXF AYAAY JBFCY GLOPP SMPH BDO GLO SPHXY JFC BBRRF BLOOM ALI LTG
Last May 18, BusinessWorld, the most read and most respected business newspaper in the Philippines, triumphantly staged the third edition of its annual BusinessWorld Economic Forum in the Grand Ballroom of Grand Hyatt Manila, in Bonifacio Global City, Taguig City.
MER GTCAP GTCXY SVTMF SMCP1 ABZPY BDOUY SM BDOUF SMGBF SMIVY SMC PNX3B PNXP PNX3A MPCFF PNX UBNC MPCIY SMGBY ABZPF BDO SMC2B SMC2A SMC2D SMC2C MPI SMC2F SMC2E AP LTG
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...